glp-1 while breastfeeding and Breastfeeding: Safety Evidence and Clinical Consider... – PlexusDx A new article from InfantRisk
Description
Acta Pharmaceutica Sinica B 4, 135-140
Novo Nordisk A/S: Wegovy pill approved in the US as first oral GLP-1 for weight management
The investigators noted that prospective studies are needed to confirm the protective benefit suggested by this retrospective analysis
It contains three patented, plant-based ingredients, each with its own small clinical study behind it: Eriomin (lemon bioflavonoids): shown to slightly increase natural GLP-1 levels in people with elevated blood sugar [1] Supresa (saffron extract): linked to reduced snacking in mildly overweight women, although some studies found no significant effects on food cravings [2][3] Morosil (red orange extract): found to support mild fat loss over 12 weeks [4] All three ingredients are studied independently , not as a combined formula
UHC Medicare Part D plans cover Wegovy only for the cardiovascular indication after the March 2024 CMS coverage update
